The US Myeloma Network (USMN) is a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring more patients benefit from breakthrough therapies.  

The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients.  

As a national clinical research infrastructure, the USMN connects leading academic centers, community oncology practices, and industry partners through a coordinated network that streamlines trial activation, expands equitable access to innovative clinical trials, and accelerates the development of more effective therapies across the continuum of myeloma care – from prevention and early intervention through relapsed and refractory disease. 

The US Myeloma Network’s primary goals are advancing access, accelerating research, and improving outcomes in myeloma care.

The USMN aims to:

• Reduce operational barriers and foster collaboration among investigators, research sites, and industry partners by shortening the time required to launch and fully enroll in high-quality clinical trials.
• Make clinical research more accessible, more collaborative, and more inclusive. The USMN will expand opportunities for clinical trial participation through culturally and linguistically responsive education, meaningful community engagement, and efforts to reduce barriers to access. The USMN aims to empower historically underrepresented and medically underserved communities to make informed decisions when it comes to participating in clinical research. By building trust, increasing awareness, and equipping patients and care partners with clear and relevant information, the USMN will work towards achieving this goal.
• Expand access and equity in clinical research. The USMN seeks to ensure equal opportunity and access to clinical research for all myeloma patients, regardless of where they live or receive treatment.  
• Collaborate with biopharmaceutical companies, leading research centers, and community oncology practices. In so doing, the USMN creates a more efficient pathway from scientific discovery to clinical practice — helping innovative therapies reach patients sooner.
• Demonstrate its commitment to innovative treatment strategies. The USMN will advance innovative treatment strategies with the potential to delay or prevent disease progression, improve long-term outcomes, bring us closer to preventing the development of active myeloma, and accelerate a cure.   

The US Myeloma Network is partnering with Sarah Cannon Development Innovations, LLC, Sarah Cannon Research Institute’s (SCRI), to support the development and execution of its clinical trials, as well as biopharmaceutical companies*, leading academic research centers, and community oncology practices to facilitate the development, initiation, and implementation of innovative clinical trials.

*The USMN’s first industry collaborator is Johnson & Johnson. 

Sarah Cannon Development Innovations, LLC (a global contract research organization of Sarah Cannon Research Institute) specializes in oncology clinical development — from first-in-human studies through studies receiving federal regulatory approval for marketing. As a key strategic partner, SCRI’s extensive experience in conducting complex oncology trials will provide the USMN with the operational expertise, infrastructure, and coordinated support needed to efficiently launch and conduct innovative clinical trials across participating sites. Together, the USMN and SCRI aim to streamline clinical trial processes, expand access to research in academic and community settings, and accelerate the translation of promising scientific advances into improved care for people living with myeloma. 

More information will become available on this IMF USMN page. Clinical trials to be conducted by the USMN will also be listed on the IMF’s Clinical Trials Matching Engine (CTME powered by SparkCures), and Clinicaltrials.gov.  

You can sign up for notifications on https://www.myeloma.org/usmn. You may also subscribe to the weekly Myeloma Minute Newsletter for the latest USMN updates and other breaking myeloma news. . 

The IMF is a nonprofit organization dedicated to accelerating the prevention and cure of myeloma and improving the quality of life for patients and families. The IMF does not manufacture the investigational treatments studied in USMN studies or benefit from the marketing of any therapeutic interventions.  

Funding for USMN comes from pharmaceutical industry sponsorships, grants, and philanthropic donations. Any payments to the IMF for the operations of USMN studies go directly towards operational costs of managing the studies.

To find out more about the US Myeloma Network, or for any other questions, please contact [email protected].